1. THAT THE COUNCIL ON PHARMACY AND CHEMISTRY REFUSE TO APPROVE LIQUID PREPARATIONS THAT ARE CLAIMED TO CONTAIN BOTH PEPSIN AND PANCREATIN. 2. THAT THE MEDICAL PROFESSION THROUGH THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION BE ADVISED OF THE FALLACY OF EMPLOYING SUCH COMBINATIONS. 3. THAT THE ATTENTION OF MANUFACTURERS BE CALLED TO THE WORTHLESSNESS OF SUCH INCOMPATIBLE LIQUID PREPARATIONS OF PEPSIN AND PANCREATIN, AND THAT THEY BE URGED TO CEASE OFFERING SUCH PRODUCTS TO THE PROFESSION. 4. THAT, SINCE THE NATIONAL FORMULARY HAS RECOGNIZED A PREPARATION OF THIS KIND UNDER THE TITLE “ELIXIR DIGESTIVUM COMPOSITUM,” THE AMERICAN PHARMACEUTICAL ASSOCIATION BE REQUESTED TO INSTRUCT ITS COMMITTEE ON THE NATIONAL FORMULARY TO OMIT THIS PREPARATION FROM THE NEXT EDITION. The recommendations of the subcommittee were adopted by the Council and publication of the report directed.--(_From The Journal A. M. A., Feb. 2, 1907._) W. A. Puckner, Secretary. PEPTO-MANGAN (GUDE) Report of the Council on Pharmacy and Chemistry The following report was adopted by the Council and its publication authorized. W. A. Puckner, Secretary. About ten years ago the M. J. Breitenbach Company circulated what pretended to be an abstract of the report of a government commission for the investigation of the anemia then prevalent in Porto Rico. The company asserted that “this report alone would suffice to establish Pepto-Mangan at once as the foremost hematinic known.” Examination of the official report of the commission[67] revealed the fact that the administration of iron in hookworm anemia was considered of secondary importance, and that of the various preparations of iron, Blaud’s pill was found to be more efficient than Pepto-Mangan (Gude). A protest[68] was made at this time by the commission against the unwarranted use of its report by the Breitenbach Company. [67] The Journal, Sept. 23, 1905, p. 934. [68] The Journal, Oct. 7, 1905, p. 1099. Later the Breitenbach Company sent out a report pretending to prove that at the Infants Hospital, Randall’s Island, New York City, Pepto-Mangan (Gude) had been found a most superior preparation in the treatment of infantile anemia. Inspection of the hospital records and daily charts of the cases disclosed[69] a remarkable disparity between the claims of the Pepto-Mangan pamphlet and the real results of treatment. And so here, also, as well as in the Porto Rico commission’s report the trials, selected by the Breitenbach Company prove the limitations and non-superiority of Pepto-Mangan. [69] The Journal, April 6, 1907, p. 1197.